|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT01470352 |
|
Date of registration:
|
09/11/2011 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
November 16, 2011 |
|
Target sample size:
|
179 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT01470352 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Israel
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- patients diagnosed with migraine based on the International Headache Society (IHS)
criteria 1 that have >4 attacks/month, both with and without aura
Exclusion Criteria:
- patients receiving any migraine preventive treatment during last 3 months or prior
treatment with amytriptiline
- other chronic pain conditions
- psychiatric, other neurological diseases, language barrier or cognitive dysfunction
Age minimum:
18 Years
Age maximum:
50 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Migraine
|
|
Intervention(s)
|
|
Drug: Placebo
|
|
Drug: Doluxetine
|
|
Primary Outcome(s)
|
|
Therapeutic response to the analgesic drugs
[Time Frame: 2 month]
|
|
Secondary ID(s)
|
|
Migrain-0265-11CTIL
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|